OPKOPKO HEALTH, INC.同业对比
OPKO HEALTH, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPK本股 | $1.3B#8 | — | 1.1x#1 | 2.2x#3 | -14.9%#7 | -324.0%#13 | -19.3%#6 | -19058.1%#13 | -13.3%#5 | 4#2 | 26.5%#5 | — |
| ETON | $1.5B#1 | — | 31.4x#12 | 18.3x#8 | 104.9%#3 | -20.4%#7 | -1.1%#5 | -9.9%#6 | -1.8%#4 | 4#2 | — | — |
| PCRX | $1.5B#2 | 104.0x#6 | 2.2x#3 | 2.0x#2 | 3.6%#5 | 107.0%#1 | 2.6%#4 | 1.0%#2 | 1.0%#3 | — | 64.2%#3 | — |
| ANAB | $1.4B#3 | 8.6x#3 | 135.5x#13 | 6.1x#5 | 157.0%#2 | 90.9%#3 | 96.7%#1 | -125.0%#12 | — | — | — | — |
| MLYS | $1.4B#4 | — | 2.6x#5 | — | — | 13.0%#5 | — | -28.1%#9 | -41.3%#7 | — | — | — |
| DMRA | $1.4B#5 | 2.9x#2 | 2.7x#7 | — | — | -878.8%#14 | — | -40.7%#11 | — | — | — | — |
| KARD | $1.3B#6 | — | 2.2x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
| LBRX | $1.3B#7 | 1.8x#1 | 4.0x#11 | — | — | 60.1%#4 | — | -7.6%#5 | — | — | 154.2%#1 | — |
| OMER | $1.3B#9 | 10.4x#4 | — | 17.7x#7 | -34.0%#8 | 97.9%#2 | -166.4%#8 | — | -151.8%#9 | — | 151.7%#2 | — |
| NKTR | $1.3B#10 | — | 1.4x#2 | 23.3x#9 | -43.9%#9 | -37.8%#8 | -253.7%#9 | -18.2%#7 | -14.0%#6 | — | — | — |
| TYRA | $1.3B#11 | — | 3.6x#10 | — | — | -38.7%#10 | — | -33.9%#10 | — | — | 40.0%#4 | — |
| SNDX | $1.3B#12 | — | — | 7.4x#6 | 627.8%#1 | 10.5%#6 | -158.4%#7 | — | -143.0%#8 | — | — | — |
| RAPP | $1.2B#13 | — | 2.9x#8 | — | — | -42.4%#11 | — | -26.4%#8 | — | — | — | — |
| MNKD | $1.2B#14 | — | — | 3.4x#4 | 22.2%#4 | -78.7%#12 | 11.1%#3 | — | 2283.8%#1 | — | — | — |
| AVLN | $1.2B#15 | — | 2.9x#9 | — | — | — | — | 0.0%#3 | — | — | — | — |
| AMPH | $1.2B#16 | 16.0x#5 | 2.6x#6 | 1.6x#1 | -1.7%#6 | -38.5%#9 | 19.5%#2 | 22.0%#1 | 13.2%#2 | 5#1 | 7.2%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议